cabozantinib

01/01/2022 - "Improved clinical efficacy has been observed in renal cell carcinoma patients (RCC) with a cabozantinib exposure greater than 750 μg/L. "
01/01/2021 - "Cabozantinib is an effective treatment for metastatic renal cell carcinoma (mRCC). "
02/01/2018 - "Cabozantinib approved for first-line treatment of advanced renal cell carcinoma."
01/01/2022 - "Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)."
04/22/2023 - "The aim of our analysis was to evaluate the efficacy of cabozantinib in patients with metastatic renal cell carcinoma. "

12/01/2022 - "Our findings indicated that Cabozantinib combined with anti-HER2 mAb dramatically reduced tumor growth and increased tumor rejection (p = 0.0001). "
10/23/2023 - "Cabozantinib/ICB treatment led to tumor regression and significantly improved survival in mice with normal livers. "
01/01/2022 - "The high efficacy of cabozantinib in low angiogenic tumors allows us to speculate that its antitumor activity is not exclusively mediated by VEGFR inhibition."
04/15/2020 - "More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). "
01/01/2020 - "Initially after 2 months of cabozantinib, magnetic resonance imaging (MRI) revealed a significant reduction (44.2%) in tumor diameter from 21.7 to 12.1 cm with decreased extension into adjacent structures. "

01/01/2020 - "The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). "
01/01/2020 - "In the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). "
04/09/2022 - "Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial."
12/01/2019 - "In the CELESTIAL trial for patients with advanced hepatocellular carcinoma (HCC), cabozantinib showed improved survival compared with placebo but comes at a price. "
05/01/2023 - "Cabozantinib showed a favorable benefit-risk profile in Japanese patients with advanced hepatocellular carcinoma (HCC) in an open-label, phase II study (NCT03586973). "

10/01/2018 - "Cabozantinib improved TTD overall, with a marked improvement in patients with bone metastases at baseline. "
01/01/2020 - "Cabozantinib improved overall survival both for the group with bone metastases, with risk of death decreased by 53% (hazard ratio, 0.47; 95% confidence interval, 0.26-0.87; P=0.02) and for the group without bone metastases, decreasing the risk of death by 44% (hazard ratio, 0.56; 95% confidence interval, 0.40-0.79; P=0.001) over the standard of care. "
01/01/2020 - "To date, there are no data about the safety and efficacy of cabozantinib in mRCC with cardiac metastasis. "
10/01/2018 - "PFS, OS, and ORR were also improved with cabozantinib in patients without bone metastases. "
01/01/2015 - "In a Phase III clinical study, cabozantinib improved PFS (11.2 months versus 4.0 months in the placebo group) of patients with MTC (independently of age, bone metastases, RET status and prior treatment). "

01/01/2020 - "Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. "
01/01/2014 - "Therefore, randomized phase III studies are currently ongoing to validate the efficacy of cabozantinib in heavily pretreated prostate cancer patients."
01/01/2013 - "In a phase II clinical trial in advanced prostate cancer (PCa), cabozantinib treatment improved bone scans in 68% of evaluable patients. "
01/01/2020 - "Cabozantinib is active in advanced prostate cancer with improvement on bone scans in men on phase II trials. "
01/01/2016 - "Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer."